The DOI matches its Crossref record.
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease
Abstract
Recent clinical studies of Crohn’s disease patients demonstrated dramatic clinical responses following one i.v. infusion of a chimeric mAb to TNF-alpha (cA2). To assess the role of TNF-alpha in mucosal cytokine regulation, the effects of TNF-alpha on lamina propria mononuclear cell (LPMC) Th1 production were determined. Increased IFN-gamma production was demonstrated in anti-CD2-stimulated LPMC cultured in TNF-alpha. To determine the effects of cA2 on cytokine production, TNF-alpha- and IFN-gamma-producing cells were quantitated in LPMC from five Crohn’s disease patients treated with cA2. In all four patients who demonstrated clinical and endoscopic improvement, decreased numbers of LPMC producing IFN-gamma and TNF-alpha following CD2/CD28 activation paralleled improvement in disease activity over 8 wk. In one patient who did not improve, increased numbers of TNF-alpha- and IFN-gamma-secreting LPMC were observed. In three of four responding patients, CD2/CD28-activated PBMC demonstrated increased IFN-gamma production over 8 wk. These observations suggest that TNF-alpha may be a cofactor for mucosal Th1 responses, and improvement in clinical parameters and intestinal inflammation induced by cA2 in Crohn’s disease may be mediated by down-regulation of mucosal Th1 cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Segain, J.-P., de la Blétière, D. R., Bourreille, A., Leray, V, Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottière, H. M., & Galmiche, J.-P. (2000) · Gut · doi:10.1136/gut.47.3.397 · Cited by 1,321
Molecular Mechanisms RegulatinG Th1 Immune Responses
Szabo, S. J., Sullivan, B. M., Peng, S. L., & Glimcher, L. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.140942 · Cited by 1,019
The genetics and immunopathogenesis of inflammatory bowel disease
Cho, J. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2340 · Cited by 940
Anti–Interleukin-12 Antibody for Active Crohn's Disease
Mannon, P. J., Fuss, I. J., Mayer, L., Elson, C. O., Sandborn, W. J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033402 · Cited by 848
Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H. A., Wirtz, S., Becker, C., Atreya, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16432 · Cited by 828
NF‐κB in inflammatory bowel disease
Atreya, I., Atreya, R., & Neurath, M. F. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01953.x · Cited by 812
Hu, P., Han, Z., Couvillon, A. D., Kaufman, R. J., & Exton, J. H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3071-3084.2006 · Cited by 754
Role of Cytokines in the Pathogenesis of Inflammatory Bowel Disease
Papadakis, K. A., & Targan, S. R. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.289 · Cited by 714
Self-citationNeurath, M. F., Weigmann, B., Finotto, S., Glickman, J., Nieuwenhuis, E., Iijima, H., Mizoguchi, A., Mizoguchi, E., Mudter, J., Galle, P. R., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011956 · Cited by 607
The Genetics of Inflammatory Bowel Disease
Cho, J. H., & Weaver, C. T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.032 · Cited by 552
Martinez-Medina, M., Denizot, J., Dreux, N., Robin, F., Billard, E., Bonnet, R., Darfeuille-Michaud, A., & Barnich, N. (2014) · Gut · doi:10.1136/gutjnl-2012-304119 · Cited by 539
Säemann, M. D., Böhmig, G. A., Österreicher, C. H., Burtscher, H., Parolini, O., Diakos, C., Stöckl, J., Hörl, W. H., & Zlabinger, G. J. (2000) · The FASEB Journal · doi:10.1096/fj.00-0359fje · Cited by 482
McCarthy, J., O’Mahony, L., O’Callaghan, L., Sheil, B., Vaughan, E. E., Fitzsimons, N., Fitzgibbon, J., O’Sullivan, G. C., Kiely, B., Collins, J. K., et al. (2003) · Gut · doi:10.1136/gut.52.7.975 · Cited by 462
Baert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462
Self-citationSandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
Yan, Y., Kolachala, V., Dalmasso, G., Nguyen, H., Laroui, H., Sitaraman, S. V., & Merlin, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006073 · Cited by 410
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Pulmonary-intestinal cross-talk in mucosal inflammatory disease
Keely, S., Talley, N. J., & Hansbro, P. M. (2012) · Mucosal Immunology · doi:10.1038/mi.2011.55 · Cited by 386
Egger, B., Bajaj-Elliott, M., MacDonald, T. T., Inglin, R., Eysselein, V. E., & Büchler, M. W. (2000) · Digestion · doi:10.1159/000007822 · Cited by 384
Slifman, N. R., Gershon, S. K., Lee, J., Edwards, E. T., & Braun, M. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10758 · Cited by 383
Lissner, D., Schumann, M., Batra, A., Kredel, L.-I., Kühl, A. A., Erben, U., May, C., Schulzke, J.-D., & Siegmund, B. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000384 · Cited by 368
Tumor necrosis factor: Biology and therapeutic inhibitors
Papadakis, K. A., & Targan, S. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.18160 · Cited by 357
Self-citationAbreu, M. T., Arnold, E. T., Thomas, L. S., Gonsky, R., Zhou, Y., Hu, B., & Arditi, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110333200 · Cited by 356
Borruel, N., Carol, M., Casellas, F., Antolín, M., de Lara, F., Espín, E., Naval, J., Guarner, F., & Malagelada, J. R. (2002) · Gut · doi:10.1136/gut.51.5.659 · Cited by 326
Siegmund, B., Fantuzzi, G., Rieder, F., Gamboni-Robertson, F., Lehr, H.-A., Hartmann, G., Dinarello, C. A., Endres, S., & Eigler, A. (2001) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2001.281.4.r1264 · Cited by 288
Zhao, H., Zhang, H., Wu, H., Li, H., Liu, L., Guo, J., Li, C., Shih, D. Q., & Zhang, X. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-57 · Cited by 269
Current knowledge on psoriasis and autoimmune diseases
McCormick, T., Ayala-Fontanez, N., & Soler, D. (2016) · Psoriasis: Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 266
Kollias, G., Douni, E., Kassiotis, G., & Kontoyiannis, D. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01315.x · Cited by 263
Leptin: A pivotal mediator of intestinal inflammation in mice
Siegmund, B., Lehr, H. A., & Fantuzzi, G. (2002) · Gastroenterology · doi:10.1053/gast.2002.33631 · Cited by 261
Aktunc, E., Kayhan, B., Arasli, M., Gun, B. D., & Barut, F. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.559475 · Cited by 44
Gardiner, L.-J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263248 · Cited by 36
“The mechanism of action of Asacol (5-ASA) is not fully understood; however, some of its biological activity in IBD has been attributed to it being a PPARγ ligand [18].”
Background
Metadata
- Authors
- Plevy, S. E., Landers, C. J., Prehn, J., Carramanzana, N. M., Deem, R. L., Shealy, D., & Targan, S. R.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-12
- Volume
- 159
- Issue
- 12
- Pages
- 6276-6282
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1901931884
- Cited by
- 385
- References
- 0
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.